StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$165.92+0.61 (+0.37%)

Close on Nov 17, 2026Market cap $16.87BP/E 24.3Yield –

Neurocrine Biosciences price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Neurocrine Biosciences's price to sales ratio was 5.3× on Nov 11, 2026, against 5.7× a year earlier. Over the last 5 years it ranged from 4.3× to 8.8×, with a median of 6.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20265.3×−0.0
2025Dec 31, 20255.3×−0.9
2024Dec 31, 20246.2×−1.1
2023Dec 29, 20237.3×−1.0
2022Dec 30, 20228.3×+0.7
2021Dec 31, 20217.6×−1.0
2020Dec 31, 20208.6×−6.1
2019Dec 31, 201914.7×−1.0
2018Dec 31, 201815.6×−86.7
2017Dec 29, 2017102.3×−121.8
2016Dec 30, 2016224.1×−21.6
2015Dec 31, 2015245.8×−224.9
2014Jul 31, 2014470.6×+444.6
2013Dec 31, 201326.1×+14.3
2012Dec 31, 201211.7×+5.9
2011Dec 30, 20115.9×−95.4
2010Dec 31, 2010101.3×–

More Neurocrine Biosciences figures

See a number that looks wrong?